ImmuCell (ICCC) 10-Q2005 Q1 Quarterly report

Filed: 12 May 05, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accumulated, adequacy, adjusted, adversely, affectFirst, agreement, APB, Australia, broad, buy, coli, communicated, Cryptosporidium, demand, determined, diagnostic, distribution, domestic, dry, eligible, England, entered, equaled, European, exclusive, exploring, externally, FAS, FASB, fermentation, fiscal, forFirst, forWipe, front, fully, hired, hope, immunomagnetic, Implementation, individual, insignificant, instance, intangible, investigating, Japan, kit, knowledge, launch, lead, line, milestone, Option, ourFirst, ourMast, participation, parvum, perpetual, Pfizer, pressure, preventCryptosporidium, qualified, readily, reduced, redundancy, rely, replacement, responsible, Revised, revising, scientific, seek, specific, TCS, terminate, thanE, trained, trend, Union, upward, water, Wipesare, worldwide

Removed: accrued, Administration, AgriCell, alternative, amend, amended, antibacterial, anticipate, applied, award, back, blinded, blood, choice, collaboration, commercialize, commercialized, conduct, conducted, Cornell, cure, declined, deduction, defined, design, develop, developingMast, discontinued, DMV, dosage, Drug, economical, effectFirst, eliminate, end, equipment, event, exemption, exercise, expand, experimental, expire, FDA, fed, field, final, function, funding, generated, group, important, incurred, initiate, Institute, interest, inWipe, issuance, joint, LLC, LP, lump, mammalian, match, minimize, negative, obligation, origin, pay, paying, perform, pivotal, placebo, positive, preliminary, prior, processing, project, proprietary, recently, reduction, reliance, repayment, rule, SEC, separate, significantly, smaller, spread, state, statistically, study, subclinical, subcontractor, sum, supervision, table, unvested, USA, utilized, utilizing, venture

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ICCC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

IMMUCELL CORPORATION

SECTION 1350 CERTIFICATION

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of ImmuCell Corporation (the “Company”) for the period ending March 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael F. Brigham, President, Chief Executive Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Michael F. Brigham

Michael F. Brigham

President, Chief Executive Officer

and Principal Financial Officer

May 11, 2005